-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has been shown to be active in patients with relapsed or refractory multiple myeloma.
The study included patients with multiple myeloma between the ages of 18 and 69, and the Kanofsky performance score was above 50, and it met the international myeloma working group's diagnostic criteria for relapsed or refractory diseases .
diagnosis
From May 1, 2017 to January 20, 2019, a total of 22 patients were enrolled in the study, and 21 patients received CAR T cell infusion, and safety and activity analysis and evaluation were available.
In summary, the results of this study confirm that the combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells is feasible in patients with relapsed or refractory multiple myeloma.
CAR-T
Original source:
Zhiling Yan, et al.
ncbi.
Leave a message here